Zobrazeno 1 - 10 of 24 pro vyhledávání: '"Breij ECW"'
1
The FcRgamma chain is not essential for induction of experimental allergic encephalomyelitis (EAE) or anti-myelin antibody-mediated exacerbation of EAE
Autor: Breij, Ecw, Heijnen, P., Vloet, R., Takashi Saito, Winkel, Jgj, Dijkstra, Cd, Amor, S., Verbeek, S.
Publikováno v: Breij, E C W, Heijnen, P, Vloet, R, Saito, T, van de Winkel, J G J, Dijkstra, C D, Amor, S & Verbeek, S 2005, ' The FcRgamma chain is not essential for induction of experimental allergic encephalomyelitis (EAE) or anti-myelin antibody-mediated exacerbation of EAE ', Journal of Neuropathology and Experimental Neurology, vol. 64, no. 4, pp. 304-11 .
ResearcherID
Journal of Neuropathology and Experimental Neurology, 64(4), 304-11. Lippincott Williams and Wilkins
Macrophages are considered essential mediators in multiple sclerosis (MS) pathogenesis, presumably through myelin phagocytosis and release of inflammatory mediators. Macrophages and microglia express activating Fcgamma receptors (FcgammaRI and Fcgamm
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::70d487e8a17b0370eb49be3304394f40
https://research.vumc.nl/en/publications/d9fb4cdd-473d-42a7-ba8d-32da2ecf79b9
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
Akademický článek
An Antibody-Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy.
Autor: Bakema JE; Department of Otolaryngology | Head & Neck Surgery, Amsterdam UMC, location VU University Medical Center, Amsterdam, The Netherlands.; Genmab, Utrecht, The Netherlands., Stigter-van Walsum M; Department of Otolaryngology | Head & Neck Surgery, Amsterdam UMC, location VU University Medical Center, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Harris JR; Genmab US Inc., Plainsboro, New Jersey., Ganzevles SH; Department of Otolaryngology | Head & Neck Surgery, Amsterdam UMC, location VU University Medical Center, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, The Netherlands., Muthuswamy A; Genmab US Inc., Plainsboro, New Jersey., Houtkamp M; Genmab, Utrecht, The Netherlands., Plantinga TS; Genmab, Utrecht, The Netherlands., Bloemena E; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.; Department of Pathology, Amsterdam UMC, location VU University Medical Center, Amsterdam, The Netherlands., Brakenhoff RH; Department of Otolaryngology | Head & Neck Surgery, Amsterdam UMC, location VU University Medical Center, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Breij ECW; Genmab, Utrecht, The Netherlands., van de Ven R; Department of Otolaryngology | Head & Neck Surgery, Amsterdam UMC, location VU University Medical Center, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, The Netherlands.
Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Feb 01; Vol. 23 (2), pp. 187-198.
Zobrazit plný text záznamu
9
Akademický článek
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
Autor: Mhibik M; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Gaglione EM; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Eik D; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Herrick J; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Le J; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Ahn IE; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Chiu C; Genmab, Princeton, NJ., Wielgos-Bonvallet M; Genmab, Princeton, NJ., Hiemstra IH; Genmab, Utrecht, The Netherlands., Breij ECW; Genmab, Utrecht, The Netherlands., Chen J; Genmab, Princeton, NJ., Reilly EB; AbbVie Inc, North Chicago, IL., Epling-Burnette PK; AbbVie Inc, North Chicago, IL., Szafer-Glusman E; AbbVie Inc, Sunnyvale, CA., Sun C; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Wiestner A; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Publikováno v: Blood advances [Blood Adv] 2023 Aug 08; Vol. 7 (15), pp. 4089-4101.
Zobrazit plný text záznamu
10
Akademický článek
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity.
Autor: Hiemstra IH; Genmab B.V., Utrecht, the Netherlands., Santegoets KCM; Genmab B.V., Utrecht, the Netherlands., Janmaat ML; Genmab B.V., Utrecht, the Netherlands., De Goeij BECG; Genmab B.V., Utrecht, the Netherlands., Ten Hagen W; Genmab B.V., Utrecht, the Netherlands., van Dooremalen S; Genmab B.V., Utrecht, the Netherlands., Boross P; Genmab B.V., Utrecht, the Netherlands., van den Brakel J; Genmab B.V., Utrecht, the Netherlands., Bosgra S; Genmab B.V., Utrecht, the Netherlands., Andringa G; Genmab B.V., Utrecht, the Netherlands., van Kessel-Welmers B; Genmab B.V., Utrecht, the Netherlands., Verzijl D; Genmab B.V., Utrecht, the Netherlands., Hibbert RG; Genmab B.V., Utrecht, the Netherlands., Frerichs KA; Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Mutis T; Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., van de Donk NWCJ; Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Ahmadi T; Genmab Inc, Princeton, NJ, USA., Satijn D; Genmab B.V., Utrecht, the Netherlands., Sasser AK; Genmab Inc, Princeton, NJ, USA., Breij ECW; Genmab B.V., Utrecht, the Netherlands. Electronic address: ebj@genmab.com.
Publikováno v: EBioMedicine [EBioMedicine] 2023 Jul; Vol. 93, pp. 104663. Date of Electronic Publication: 2023 Jun 26.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje